Learn more Those following along with Telix Pharmaceuticals Limited (ASX:TLX) will no doubt be intrigued by the recent purchase of shares by Christian Behrenbruch, Co-Founder of the company, who spent ...

Earlier this week, Telix Pharmaceuticals reported Phase 2 OPTIMAL-PSMA trial dosimetry results for its second-generation prostate cancer candidate TLX597-Tx, showing low radiation uptake in key ...

TLX597-Tx is a PSMA1-targeting small molecule radioligand therapy (RLT) candidate, designed to improve quality-of-life and efficacy in ...

Telix Pharmaceuticals ( (AU:TLX) ) has issued an announcement.

With its latest obesity play appearing to pay off, Regeneron has turned its attention to radiopharmaceuticals. | With its latest obesity play appearing to pay off, Regeneron has turned its attention ...

Regeneron Pharmaceuticals (NASDAQ:REGN) has entered into a strategic collaboration with Telix Pharmaceuticals (NASDAQ:TLX) to develop and commercialize radiopharmaceutical therapies targeting cancer.

MELBOURNE, Australia and INDIANAPOLIS, May 1, 2026 /PRNewswire/ -- Telix Pharmaceuticals Limited (ASX: TLX, NASDAQ: TLX, \"Telix\") today announces that the marketing authorization application (MAA) ...

TLX101-Px is also being developed as a patient selection and response assessment tool for Telix’s glioblastoma therapy candidate TLX101-Tx (iodofalan 131 I), which has been granted orphan drug ...

Telix Pharmaceuticals Limited (NASDAQ:TLX) is among the best Australian stocks to buy in 2026. Telix Pharmaceuticals Limited ...

Professor Emmett will showcase data from her OPTIMAL-PSMA 2 investigator-initiated trial of TLX597-Tx ( 177 Lu-DOTA-PSMA), Telix’s novel second generation small molecule candidate being developed to ...

Telix contributes end-to-end radiopharma capabilities, including isotope selection, radiochemistry, scalable manufacturing, and a global distribution network tailored to short half-life radioisotopes.

Telix Pharmaceuticals Ltd (ASX:TLX) has delivered a sharp reminder of how quickly sentiment can swing in biotech — with a blockbuster partnership sending shares surging earlier this week, only for a ...